Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxinshi tablet for exercise tolerance in chronic coronary syndrome
ChiCTR2300074650Phase 4Recruiting
- Sponsor
- Beijing University of Chinese Medicine
- Start
- May 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of yangxinshi in Chronic Coronary Syndrome (CCS) (2 arms), sponsored by Beijing University of Chinese Medicine. Primary endpoints: Cardiopulmonary exercise test: metabolic equivalents and Cardiopulmonary exercise test: peak oxygen uptake. Started May 2023; status: recruiting.
02
Drugs
yangxinshi
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on ChiCTR2300074650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074650.